bullish
Innovent Biologics Inc (1801.HK) - Capable of Surviving “this Winter”
308 Views04 Apr 2022 07:57
After continuous pullback, investors may lose interest in Innovent. However, it still has investment value based on pipeline, resources, R&D and technology platforms.It could be the one that wins out.
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- China Healthcare Weekly (Apr.8)-Surgical Robots Pricing Rules,America COMPETES Act,COVID-19 Sequelae10 Apr 2022
- Medlive Technology (2192.HK) - The Logic Has Shaken07 Apr 2022
- JD Health (6618.HK) 2021 Results - The Logic and the Outlook06 Apr 2022
- BeiGene Ltd (6160.HK/688235.CH) - There Is No Way to Retreat08 Mar 2022
- Shanghai Junshi Bioscience (1877.HK) - Will Junshi Progress or Go Backwards Instead?14 Dec 2021
- Innovent Biologics (1801.HK) - The Strength and the Concerns31 Aug 2021
x